{
  "symbol": "BCAX",
  "company_name": "Bicara Therapeutics Inc",
  "ir_website": "https://ir.bicara.com/",
  "structured_data": [
    {
      "section_name": "News & Events",
      "links": [
        {
          "title": "Press Releases",
          "url": "https://ir.bicara.com/news-events/press-releases",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb93586/themes/site/client_site_202/local/img/hero-img.jpg)\n\n# Press Releases\n\nYear All202420232022\n\nFilter\n\n[Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update](/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2024-financial-results)\n\nNov 12, 2024 \n\n[Read More](/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2024-financial-results)\n\n[Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference](/news-releases/news-release-details/bicara-therapeutics-present-stifel-2024-healthcare-conference)\n\nNov 11, 2024 \n\n[Read More](/news-releases/news-release-details/bicara-therapeutics-present-stifel-2024-healthcare-conference)\n\n[Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares](/news-releases/news-release-details/bicara-therapeutics-announces-closing-362-million-initial-public)\n\nSep 16, 2024 \n\n[Read More](/news-releases/news-release-details/bicara-therapeutics-announces-closing-362-million-initial-public)\n\n[Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering](/news-releases/news-release-details/bicara-therapeutics-announces-pricing-upsized-initial-public)\n\nSep 12, 2024 \n\n[Read More](/news-releases/news-release-details/bicara-therapeutics-announces-pricing-upsized-initial-public)\n\n[Bicara Therapeutics Expands Board of Directors with Appointments of Mike Powell, Ph.D., and Christopher Bowden, M.D.](/news-releases/news-release-details/bicara-therapeutics-expands-board-directors-appointments-mike)\n\nAug 15, 2024 \n\n[Read More](/news-releases/news-release-details/bicara-therapeutics-expands-board-directors-appointments-mike)\n\n[Bicara Therapeutics Reports Updated Interim Phase 1/1b Data of Ficerafusp Alfa (BCA101) in 1L HPV-negative Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)](/news-releases/news-release-details/bicara-therapeutics-reports-updated-interim-phase-11b-data)\n\nJun 27, 2024 \n\n[Read More](/news-releases/news-release-details/bicara-therapeutics-reports-updated-interim-phase-11b-data)\n\n[Bicara Therapeutics Expands Clinical Team with Appointments of Jeltje Schulten, M.D., MBA, as SVP of Clinical and Medical Affairs and Rita Dalal, MBBS, MPH, as VP of Clinical Development](/news-releases/news-release-details/bicara-therapeutics-expands-clinical-team-appointments-jeltje)\n\nMar 26, 2024 \n\n[Read More](/news-releases/news-release-details/bicara-therapeutics-expands-clinical-team-appointments-jeltje)\n\n[Bicara Therapeutics to Participate in Upcoming March Investor Conferences](/news-releases/news-release-details/bicara-therapeutics-participate-upcoming-march-investor)\n\nFeb 27, 2024 \n\n[Read More](/news-releases/news-release-details/bicara-therapeutics-participate-upcoming-march-investor)\n\n[Bicara Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference](/news-releases/news-release-details/bicara-therapeutics-present-42nd-annual-jp-morgan-healthcare)\n\nJan 02, 2024 \n\n[Read More](/news-releases/news-release-details/bicara-therapeutics-present-42nd-annual-jp-morgan-healthcare)\n"
        },
        {
          "title": "Events & Presentations",
          "url": "https://ir.bicara.com/news-events/events-and-presentations",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb93586/themes/site/client_site_202/local/img/hero-img.jpg)\n\n# Events & Presentations\n\n## Latest Presentation\n\n[Corporate Presentation - November 2024](/static-files/38ed8782-b7fe-4c9a-9628-fee66563c014)\n\n## Upcoming Events\n\nThere are no upcoming events scheduled at this time.\n\n## Past Events\n\n[Stifel 2024 Healthcare Conference](/events/event-details/stifel-2024-healthcare-conference)\n\nNov 19, 2024 9:10 AM EST\n\n[Click here for Webcast](https://wsw.com/webcast/stifel96/bcax/2072916)\n"
        }
      ]
    },
    {
      "section_name": "Corporate Governance",
      "links": [
        {
          "title": "Governance Overview",
          "url": "https://ir.bicara.com/corporate-governance/governance-overview",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb93586/themes/site/client_site_202/local/img/hero-img.jpg)\n\n# Governance Overview\n\n## Corporate Governance Overview\n\nThe Board of Directors of Bicara Therapeutics, Inc. (the “Company”) sets high standards for the Company’s employees, officers and directors. Implicit in this philosophy is the importance of sound corporate governance. It is the duty of the Board of Directors to serve as a prudent fiduciary for shareholders and to oversee the management of the Company’s business. To fulfill its responsibilities and to discharge its duty, the Board of Directors follows the procedures and standards that are set forth in these guidelines. These guidelines are subject to modification from time to time as the Board of Directors deems appropriate in the best interests of the Company or as required by applicable laws and regulations.\n\n## Governance Documents\n\n[Code of Business Conduct and Ethics ](/static-files/43e281ed-94d0-435e-90b7-ec78a928def7)\n\n[Corporate Governance Guidelines](/static-files/62569002-5a5a-4aac-a4d4-59932b437b9a)\n\n## Committee Charters\n\n[Audit Committee Charter](/static-files/77c4b799-285d-4ee1-b749-130e66699e3b)\n\n[Compensation Committee Charter](/static-files/ba51dca6-79f3-430c-a3de-a2508a311b02)\n\n[Nominating and Corporate Governance Committee Charter](/static-files/6268f9b7-fcf4-431a-b603-cf37bedffbe7)\n"
        },
        {
          "title": "Leadership",
          "url": "https://bicara.com/about/?teamType=leadership#team-section",
          "content": "\n"
        },
        {
          "title": "Board of Directors",
          "url": "https://bicara.com/about/?teamType=board-of-directors#team-section",
          "content": "\n"
        },
        {
          "title": "Committee Composition",
          "url": "https://ir.bicara.com/corporate-governance/committee-composition",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb93586/themes/site/client_site_202/local/img/hero-img.jpg)\n\n# Committee Composition\n\nDirector Name | [Audit Committee](/static-files/77c4b799-285d-4ee1-b749-130e66699e3b) | [Compensation Committee](/static-files/ba51dca6-79f3-430c-a3de-a2508a311b02) | [Nominating and Corporate Governance Committee](/static-files/6268f9b7-fcf4-431a-b603-cf37bedffbe7)  \n---|---|---|---  \nMike Powell, PhD  | of the Audit Committee[Audit Committee](/static-files/77c4b799-285d-4ee1-b749-130e66699e3b) | of the Compensation Committee[Compensation Committee](/static-files/ba51dca6-79f3-430c-a3de-a2508a311b02)  \nChristopher Bowden, MD  | of the Compensation Committee[Compensation Committee](/static-files/ba51dca6-79f3-430c-a3de-a2508a311b02)  \nKate Haviland, MBA  | of the Compensation Committee[Compensation Committee](/static-files/ba51dca6-79f3-430c-a3de-a2508a311b02)  \nNils Lonberg, PhD  | of the Nominating and Corporate Governance Committee[Nominating and Corporate Governance Committee](/static-files/6268f9b7-fcf4-431a-b603-cf37bedffbe7)  \nKiran Mazumdar-Shaw  | of the Nominating and Corporate Governance Committee[Nominating and Corporate Governance Committee](/static-files/6268f9b7-fcf4-431a-b603-cf37bedffbe7)  \nCarolyn Ng, PhD  | of the Audit Committee[Audit Committee](/static-files/77c4b799-285d-4ee1-b749-130e66699e3b)  \nScott Robertson, MBA  | of the Audit Committee[Audit Committee](/static-files/77c4b799-285d-4ee1-b749-130e66699e3b)  \nJake Simson, PhD  | of the Nominating and Corporate Governance Committee[Nominating and Corporate Governance Committee](/static-files/6268f9b7-fcf4-431a-b603-cf37bedffbe7)  \n  \nLegend Chair icon =  Chair Member icon =  Member Chair of the Board icon =  Chair of the Board\n"
        }
      ]
    },
    {
      "section_name": "Stock Information",
      "links": [
        {
          "title": "Stock Quote & Chart",
          "url": "https://ir.bicara.com/stock-information/stock-quote-chart",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb93586/themes/site/client_site_202/local/img/hero-img.jpg)\n\n# Stock Quote & Chart\n\n## Stock Quote\n\nChange\n\nVolume\n\nToday's Open\n\nPrevious Close\n\nToday's High\n\nToday's Low\n\n52 Week High\n\n52 Week Low\n\n## Stock Chart\n\nMinimum 15 minutes delayed. Source: LSEG\n"
        },
        {
          "title": "Analyst Coverage",
          "url": "https://ir.bicara.com/stock-information/analyst-coverage",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb93586/themes/site/client_site_202/local/img/hero-img.jpg)\n\n# Analyst Coverage\n\nAnalyst Coverage Firm | Analyst  \n---|---  \nCantor Fitzgerald |  Eric Schmidt   \nGoldman Sachs  |  Richard Law   \nMorgan Stanley |  Judah Frommer   \nRodman & Renshaw  |  Tony Butler   \nStifel |  Stephen Willey   \nTD Cowen |  Tyler Van Buren   \n  \nBicara Therapeutics Inc. is followed by the analysts listed. Please note that any opinions, estimates or forecasts regarding Bicara Therapeutics Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Bicara Therapeutics Inc. or its management. Bicara Therapeutics Inc. does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.\n"
        }
      ]
    },
    {
      "section_name": "Financials & Filings",
      "links": [
        {
          "title": "SEC Filings",
          "url": "https://ir.bicara.com/financials-filings/sec-filings",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb93586/themes/site/client_site_202/local/img/hero-img.jpg)\n\n# SEC Filings\n\nGroup All3,4,5Annual FilingsCurrent ReportsMergers & AcquisitionsOtherProxy FilingsQuarterly FilingsRegistration Statements\n\nFiling year All2024202320222021\n\nFilter\n\n[Filing Date](?items_per_page=10&order=field_nir_sec_date_filed&sort=asc \"Sort by Filing Date in ascending order\") | [Form](?items_per_page=10&order=field_nir_sec_form&sort=asc \"Sort by Form\") | [Description](?items_per_page=10&order=field_nir_sec_description&sort=asc \"Sort by Description\") | Filing Group | View  \n---|---|---|---|---  \nNov 12, 2024 |  [8-K](/sec-filings/sec-filing/8-k/0001193125-24-255166) |  Report of unscheduled material events or corporate event |  Current Reports |  [View HTML](/node/7011/html) [0001193125-24-255166.pdf](/static-files/56cb8029-4b63-45f6-be1a-707d6600be60) [0001193125-24-255166.rtf](/static-files/73e15277-b748-4776-8332-27f0c87e4fad) [0001193125-24-255166.xls](/static-files/8877d849-92f7-495a-9621-c61301425871) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/8-k/0001193125-24-255166)  \nNov 12, 2024 |  [10-Q](/sec-filings/sec-filing/10-q/0002023658-24-000002) |  Quarterly report which provides a continuing view of a company's financial position |  Quarterly Filings |  [View HTML](/node/7021/html) [0002023658-24-000002.pdf](/static-files/e2bbc554-30b1-43c1-8e24-3052e12c2693) [0002023658-24-000002.rtf](/static-files/77e113f8-26fd-49e6-9eec-d6dce2fa0be8) [0002023658-24-000002.xls](/static-files/5139cc80-6917-4b7f-9563-dc734ab62d93) [EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/sec-filings/sec-filing/10-q/0002023658-24-000002)  \nSep 26, 2024 |  [SC 13G](/sec-filings/sec-filing/sc-13g/0001104659-24-103150) |  A statement of beneficial ownership of common stock by certain persons |  Other |  [View HTML](/node/6896/html) [0001104659-24-103150.pdf](/static-files/2856dc28-f237-4baf-a3ae-2e8f217fe897) [0001104659-24-103150.rtf](/static-files/bbf82585-84d6-4a08-90a7-b84f6c818b8c) [0001104659-24-103150.xls](/static-files/e92f2c79-9f5c-4e04-849a-52b81eff49a1)  \nSep 26, 2024 |  [SC 13G](/sec-filings/sec-filing/sc-13g/0001193125-24-226971) |  A statement of beneficial ownership of common stock by certain persons |  Other |  [View HTML](/node/6901/html) [0001193125-24-226971.pdf](/static-files/bf15949a-07b7-455e-92b6-7ecbbe3660ac) [0001193125-24-226971.rtf](/static-files/419cca42-ba3e-4616-86a6-2ec815489ec1) [0001193125-24-226971.xls](/static-files/03ac800a-9b12-40be-9a4c-850fedb8e92a)  \nSep 23, 2024 |  [SC 13D](/sec-filings/sec-filing/sc-13d/0001104659-24-102048) |  Filing by person(s) reporting owned shares of common stock in a public company >5% |  Other |  [View HTML](/node/6891/html) [0001104659-24-102048.pdf](/static-files/19bd6be4-1a5a-4caf-87c7-7fcebcfa9935) [0001104659-24-102048.rtf](/static-files/45aebc2a-4b38-4540-945c-f9328cf0c5bc)  \nSep 18, 2024 |  [4](/sec-filings/sec-filing/4/0000950170-24-107660) |  Statement of changes in beneficial ownership of securities |  3,4,5 |  [View HTML](/node/6861/html) [0000950170-24-107660.pdf](/static-files/11941252-a056-43b4-88dd-b4442c8850fc) [0000950170-24-107660.rtf](/static-files/755f4613-3270-4801-b21f-265c18d44d44) [0000950170-24-107660.xls](/static-files/c55ab12d-a80c-43e2-baf1-a0699d9fa764)  \nSep 18, 2024 |  [4](/sec-filings/sec-filing/4/0000950170-24-107661) |  Statement of changes in beneficial ownership of securities |  3,4,5 |  [View HTML](/node/6866/html) [0000950170-24-107661.pdf](/static-files/acb05073-7c2d-41a9-94bf-6325e4204cbe) [0000950170-24-107661.rtf](/static-files/deac1122-0263-4f05-b833-2aa1674574f9) [0000950170-24-107661.xls](/static-files/12e5d90e-07c7-4bad-8a07-ce61ad4eb5d2)  \nSep 18, 2024 |  [SC 13G](/sec-filings/sec-filing/sc-13g/0000315066-24-001989) |  A statement of beneficial ownership of common stock by certain persons |  Other |  [View HTML](/node/6871/html) [0000315066-24-001989.pdf](/static-files/c484719f-2c79-44e0-8a98-80edb2021455) [0000315066-24-001989.rtf](/static-files/100f9125-c631-4895-a6b7-4db2996f3b6d)  \nSep 18, 2024 |  [4](/sec-filings/sec-filing/4/0001999371-24-012102) |  Statement of changes in beneficial ownership of securities |  3,4,5 |  [View HTML](/node/6876/html) [0001999371-24-012102.pdf](/static-files/9b5642e3-35e2-4974-abdf-5b234ba593d6) [0001999371-24-012102.rtf](/static-files/7c41b272-3cac-456e-9870-b4deeded1ed2) [0001999371-24-012102.xls](/static-files/9dd90374-fb2c-4e50-8ea7-4dd9bded98c2)  \nSep 18, 2024 |  [SC 13D](/sec-filings/sec-filing/sc-13d/0001999371-24-012103) |  Filing by person(s) reporting owned shares of common stock in a public company >5% |  Other |  [View HTML](/node/6881/html) [0001999371-24-012103.pdf](/static-files/b1fef2d5-542b-4b51-a19e-6f8a5c795fa8) [0001999371-24-012103.rtf](/static-files/cb91baa1-707e-455e-a235-d17c2e906185) [0001999371-24-012103.xls](/static-files/b58a10ce-960e-4028-8394-3632b6ab199b)  \n  \nDisplaying 1 - 10 of 63 results\n\nData provided by [Kaleidoscope](https://www.kscope.io).\n"
        }
      ]
    },
    {
      "section_name": "Resources",
      "links": [
        {
          "title": "Investor FAQs",
          "url": "https://ir.bicara.com/resources/investor-faqs",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb93586/themes/site/client_site_202/local/img/hero-img.jpg)\n\n# Investor FAQs\n\n[Show All](#)\n\nPress space to expand and collapse this section\n\nWhere is Bicara Therapeutics’ corporate headquarters?\n\nBicara Therapeutics is headquartered at 116 Huntington Avenue, Suite 703, Boston, MA 02116.\n\nPress space to expand and collapse this section\n\nWhen was Bicara Therapeutics founded?\n\nBicara Therapeutics was incorporated in December 2018 in Delaware.\n\nPress space to expand and collapse this section\n\nOn which exchange is Bicara Therapeutics listed, what is the ticker symbol and when did it go public?\n\nBicara Therapeutics’ stock is traded on the NASDAQ Global Market under the ticker symbol “BCAX”.\n\nPress space to expand and collapse this section\n\nWhen is Bicara Therapeutics fiscal year-end?\n\nBicara Therapeutics’ fiscal year-end is December 31st.\n\nPress space to expand and collapse this section\n\nWho is Bicara Therapeutics transfer agent?\n\nBicara Therapeutics’ transfer agent is:Computershare Trust Company, N.A.web.queries@computershare.com1-800-736-3001, option 1 (U.S.)1-781-575-3100, option 1 (non-U.S.)\n\nPress space to expand and collapse this section\n\nWho is Bicara’s outside legal counsel and independent auditor?\n\nBicara Therapeutics’ legal counsel is Goodwin Procter LLP. The company’s independent auditor is KPMG.\n\nPress space to expand and collapse this section\n\nWhere can I find the latest corporate news releases and financial reports?\n\nCorporate news can be found in the [News & Events](/news-events/press-releases) section of our Investors webpage. Quarterly and annual reports, as well as other SEC filings, can be found in the [Financials](/financials-filings/sec-filings) section of our Investors webpage or directly from the SEC at www.sec.gov.\n\nPress space to expand and collapse this section\n\nWhere can I find copies of Bicara Therapeutics’ financial documents, including annual reports (Form-10K) and quarterly reports (Form 10-Q)?\n\nThe Company’s financial documents can be found in the [Financials](/financials-filings/sec-filings) section of our Investors webpage or directly from the SEC at www.sec.gov.\n\nPress space to expand and collapse this section\n\nWhen and where is the Annual Stockholders’ Meeting?\n\nThe date and location of Bicara’s next annual meeting will be communicated prior to the meeting date.\n\nPress space to expand and collapse this section\n\nWhom should I contact regarding investor inquiries?\n\nPlease email ir@bicara.com.\n\nPress space to expand and collapse this section\n\nHow can I sign up to receive Bicara Therapeutics’ press releases and other company news?\n\nAlerts can be set up from the “[Email Alerts](/resources/email-alerts)” section of the “Investors” page.\n\nPress space to expand and collapse this section\n\nWhich analysts cover Bicara?\n\nOur current analyst coverage can be found in the [Stock Information](/stock-information/analyst-coverage) section of our Investors webpage.\n\nPress space to expand and collapse this section\n\nHow can I purchase shares?\n\nShares can be purchased through a stockbroker of your choice.\n\nPress space to expand and collapse this section\n\nDoes Bicara have a direct stock purchase plan? \n\nBicara does not currently have a direct stock purchase plan.\n"
        },
        {
          "title": "Contact Us",
          "url": "https://ir.bicara.com/resources/contact-us",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb93586/themes/site/client_site_202/local/img/hero-img.jpg)\n\n# Contact Us\n\n##### INVESTORS\n\nir@bicara.com\n\nName* Required\n\nEmail* Required\n\nSubject* Required\n\nComments* Required\n\nSubmit\n\nLeave this field blank\n\nreCAPTCHA response\n"
        },
        {
          "title": "Email Alerts",
          "url": "https://ir.bicara.com/resources/email-alerts",
          "content": "[Skip to content](#lfg-main-content)\n\n![](/sites/g/files/knoqqb93586/themes/site/client_site_202/local/img/hero-img.jpg)\n\n# Email Alerts\n\nTo opt-in for investor email alerts, please select at least one alert option and enter your email address in the field below. After submitting your request, an activation email will be sent to the address provided. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time. If you would like to opt out of email alerts, you can [unsubscribe here](/unsubscribe). \n\nRequired fields denoted by an asterisk ().\n\nAlert type* Required\n\nEnd-of-Day Stock Quote\n\nSEC Filing\n\nEvents\n\nPress Releases\n\nPresentations\n\nWeekly Summary\n\nEmail* Required\n\nSubmit\n\nLeave this field blank\n\nreCAPTCHA response\n"
        }
      ]
    },
    {
      "section_name": "Latest Presentations",
      "links": [
        {
          "title": "Corporate Presentation - November 2024",
          "url": "https://ir.bicara.com/static-files/38ed8782-b7fe-4c9a-9628-fee66563c014",
          "content": "\n"
        }
      ]
    }
  ]
}